Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaso²R: Early Argipressin in Norepinephrine-refractory Vasoplegic Shock
NCT07063680Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Apr 2026
- Primary completion
- Jan 2029
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of vasopressin in vasoplegic shock, sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Started Apr 2026; status: recruiting.
02
Drugs
vasopressin
03
Conditions
vasoplegic shock
Beyond the preview
Go deeper on NCT07063680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07063680.